Nancy Beesley has been appointed to Dermavant Sciences’ Board of Directors. She joins Dermavant with more than 25 years of experience in commercializing and branding therapeutics for the treatment of various dermatological, ophthalmic, and neurological conditions and rare diseases.

“Nancy is an esteemed member of the pharmaceutical community who has dedicated her career to the dynamic and successful launches of a number of novel therapeutics, spanning multiple disease verticals and indications,” says Todd Zavodnick, Chief Executive Officer of Dermavant. “I believe Nancy will be an invaluable resource to Dermavant as we finalize our commercialization efforts ahead of a potential FDA approval of tapinarof for the treatment of plaque psoriasis in adults in the second quarter of 2022.”

“I am delighted to be joining Dermavant at such a pivotal time in the company’s history,” says Ms. Beesley. “The results that tapinarof has shown in Dermavant’s clinical studies point to a potentially bright future for the novel, once-daily, topical psoriasis treatment in adults, subject to FDA approval. In addition, Todd has assembled a world-class team at Dermavant to not only drive innovation in immuno-dermatology, but to bring new therapeutic treatments to the underserved patient populations who need them.”

Ms. Beesley serves as President and Co-Founder of HCB Health, a full-service healthcare marketing agency. At HCB, she has worked on various campaigns in disease spaces such as dermatology, aesthetics, wound care, rare disease, ophthalmology, and neurology, helping to launch more than 70 products. Prior to HCB Health, Ms. Beesley served as Partner and Chief Strategy Officer at The Olson Group. She began her career at Girgenti Hughes Butler & McDowell (Ogilvy Healthworld), working on pharmaceutical and drug-in-device therapies within the respiratory and cardiovascular spheres. Ms. Beesley has been named one of Pharma Voice’s Top 100 Most Inspiring People in Healthcare. She has also been included in Austin’s “Women to Watch” list, and in Med Ad News’ Agency of the Year awards.